Lung imaging is furthermore a challenge in MRI because of the predominance of air within the lungs and associated susceptibility issues as well as low signal to noise of the inflated lung parenchyma. Cardiac and respiratory triggered or breath hold sequences allow diagnostic imaging, however a comparable image quality with computed tomography is still difficult to achieve.
Assumptions for lung MRI:
Very short transverse relaxation times and significant diffusion yielding short T2 (30-70 msec), short T2* (1-3 msec), and additional long T1 relaxation times (1300-1500 msec).
•
The extreme short T2 values are responsible for a fast signal decay during a single shot readout, resulting in blurring.
Short name: NC100150, PEG-feron, generic name: Feruglose, preliminary trade name: Clariscan™
NC100150 injection is the code name for an USPIO (ultrasmall superparamagnetic iron oxide) MRIcontrast agent under development. Microvessel permeability depends on functional and morphologic characteristics of cancer vessels
and on physicochemical properties of the injected contrast mediummolecule.
USPIO particles have a favorable pharmacological and tolerance profile and are being tested clinically of the potential for the quantitative
characterization of tumor microvasculature and specifically for measures of the microvessel permeability.
Iron-based products take advantage of their large molecular size, which prevents diffusion into body tissues. These agents are disposed of by the liver and spleen as particulate matter.
NC100150 Injection (Nycomed Amersham, Amersham Health ) consists of USPIO particles that are composed of single crystals (4- to 7-nm diameter) and stabilized with a carbohydrate polyethylene glycol (PEG) coat. The iron oxide particles
have to be suspended in an isotonic glucose solution. The final diameter of an USPIO particle is approximately 20 nm. Blood pool half-life is more than two hours in humans; the particles are taken up by the mononuclear
phagocyte system and distributed mainly to the liver and spleen.
NC100150 would compete with the contrast agentsFerumoxytol from AMAG Pharmaceuticals, Inc. and Vasovist™ from EPIX Pharmaceuticals, Inc., but at this time the development of NC100150 Injection/Clariscan™ is discontinued.
Short name: P760, chemical compound: tetraazacyclododecanetetraacetic acid (DOTA), central moity: Gd
P760 (Guerbet SA) is a low-diffusiongadolinium complex with a macrocyclic core based on a tetraazacyclododecanetetraacetic acid (DOTA)
structure, which is substituted with bulky hydrophilic
groups.
The relaxivity of P760 at 0.47 T is very high compared to Gd-DOTA.